BioVision 10/17

PRODUCT: PT-2385

ALTERNATE NAMES: (S)-3-((2,2-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-

1H-inden-4-yl)oxy)-5-fluorobenzonitrile; PT2385

CATALOG NUMBER: B1920-5,25

**AMOUNT:** 5 mg, 25 mg

STRUCTURE:

HANDLING:

MOLECULAR FORMULA: C<sub>17</sub>H<sub>12</sub>F<sub>3</sub>NO<sub>4</sub>S

MOLECULAR WEIGHT: 383.34

**CAS NUMBER:** 1672665-49-4

APPEARANCE: Crystalline solid

SOLUBILITY: DMSO

PURITY: ≥98% by HPLC

STORAGE: Store at -20 °C. Protect from air and light

**DESCRIPTION:** PT-2385 is a potent ad selective inhibitor of hypoxia inducible

factor (HIF-2 $\alpha$ ) with potential antineoplastic activity. PT-2385 selectively disrupts the heterodimerization of HIF-2 $\alpha$  with HIF-1 $\beta$ . Very effective in blocking cancer cell growth, proliferation, and tumor angiogenesis characteristic in clear cell renal cell

carcinoma (ccRCC).

REFERENCES: Toledo, R.A. (2017). Endocr. Relat. Cancer 24, C9-C19.

Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure. RELATED PRODUCTS:

BAY 87-2243 (Cat. No. B1878) Chetomin (Cat. No. 2180) Emetine dihydrochloride (1970)

KC7F2 (Cat. No. 9641)

PT-2385 (B1920)

PX 12 (Cat. No. 2217)

PX-478 HCI (Cat. No. B1033)

USAGE: FOR RESEARCH USE ONLY! Not to be used in humans